Clinical Trial Update: Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED) [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy study of IL-10 (Tenovil) to prevent post-ERCP pancreatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis

Drugs mentioned

• Tenovil (interleukin-10)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bile Duct Diseases, Biliary Tract Diseases | Phase 2 | Status: TERMINATED